Key points are not available for this paper at this time.
Congress has modified regulations of the Food and Drug Administration to promote research assessing the efficacy and safety of drugs in children. The authors examine how this legislation has affected pediatric drug development and research over the past 20 years and discuss options for additional reforms to accelerate progress in this area.
Bourgeois et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: